Ocular side effects of Trametinib and Dabrafenib: a case report

Ocular side effects of Trametinib and Dabrafenib: a case report

Abstract A 53-year-old man who has stage 4 non-small cell lung carcinoma and treated with Dabrafenib-Trametinib combination chemotherapy; presented with decreased bilateral visual acuity. We checked out slit lamp examination, fundoscopy, optical coherence tomography and fundus fluorescein angiograph...

Full description

Bibliographic Details
Main Authors:	Bilge Tarım, Meltem Kılıç
Format:	Article
Language:	English
Published:	SpringerOpen 2023-04-01
Series:	Journal of Ophthalmic Inflammation and Infection
Subjects:	Trametinib Dabrafenib Uveitis Cystoid macular edema Serous retinal detachment
Online Access:	https://doi.org/10.1186/s12348-023-00339-0

Similar Items

Ocular toxicity due to Trametinib and Dabrafenib
by: Stephanie Sarny, et al.
Published: (2017-08-01)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
by: Alia Thawer, et al.
Published: (2021-09-01)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma
by: Matthew Chang, et al.
Published: (2021-06-01)

Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01)

Two cases of acute‐onset cystoid macular edema and serous retinal detachment associated with combined use of encorafenib and binimetinib for advanced melanoma: A possible confounding risk for drug intolerance
by: Takumi Hasegawa, et al.
Published: (2023-12-01)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
by: Sandip Ganguly, et al.
Published: (2021-09-01)

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation
by: Baptiste Le Calvez, et al.
Published: (2020-07-01)

Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy
by: Marrium Sultan Dar, et al.
Published: (2024-01-01)

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022-04-01)

Uveitis as a Result of MAP Kinase Pathway Inhibition
by: Lavnish Joshi, et al.
Published: (2013-11-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1
by: Gil Awada, et al.
Published: (2020-09-01)

Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients
by: Xue Peng, et al.
Published: (2023-01-01)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
by: Nora Isberner, et al.
Published: (2022-09-01)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
by: Marilda Mormando, et al.
Published: (2020-07-01)

[Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market]
by: Lorenzo Pradelli, et al.
Published: (2016-12-01)

Hyperreflective foci as biomarkers for inflammation in diabetic macular edema: Retrospective analysis of treatment naïve eyes from south India
by: M Arthi, et al.
Published: (2021-01-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
by: Walid Shalata, et al.
Published: (2023-02-01)

Evaluation of systemic risk factors in different optical coherence tomographic patterns of diabetic macular edema
by: Durgul Acan, et al.
Published: (2018-07-01)

Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
by: Ji Eun Shin, et al.
Published: (2022-11-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
by: Maria Chiara Tronconi, et al.
Published: (2022-05-01)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
by: Carola Berking, et al.
Published: (2023-09-01)

Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
by: Yang Yang, et al.
Published: (2021-12-01)

Clinical Response of Advanced Lung Adenocarcinoma with Class III BRAF G466V Missense Mutation to Dabrafenib and Trametinib: A Case Report
by: Fang R, et al.
Published: (2024-01-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
by: Victoria G. Atkinson, et al.
Published: (2021-05-01)

Pneumatosis intestinalis in a radioactive iodine-refractory metastasic thyroid papillary carcinoma with BRAFV600E mutation treated with dabrafenib–trametinib: a case report
by: M. C. Martín-Soberón, et al.
Published: (2021-03-01)

Prevalence of Serous Macular Detachment in Recurrent Macular Edema Secondary to Retinal Vein Occlusion
by: Mehmet Ali Şekeroğlu, et al.
Published: (2022-08-01)

An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAFV600E mutation responds to dabrafenib and trametinib: a case report and literature review
by: Ruoxin Fang, et al.
Published: (2023-07-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

Epiretinal membrane and cystoid macular edema as predictive factors of recurrent proliferative vitreoretinopathy
by: Xu K, et al.
Published: (2017-10-01)

Intermediate Uveitis as the Initial and Only Presentation of Syphilis
by: Sevcan Yıldız Balcı, et al.
Published: (2019-10-01)

Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAF V600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis
by: Eriko Nakamura, et al.
Published: (2024-01-01)

Surgical Success Rate of Scleral Buckling Surgery and Postoperative Incidence of Cystoid Macular Edema: 10 Years of Experience at a Single Academic Hospital
by: Amaka Watanabe, et al.
Published: (2022-09-01)

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
by: Gudrun Piringer, et al.
Published: (2023-05-01)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
by: Michele Del Vecchio, et al.
Published: (2023-03-01)